Nielsen’s Melissa Davies offers a summary of her experience at the recent FDA hearings which focused on how healthcare and pharmaceutical companies can responsibly engage consumers online and through social media.

On Friday, November 13, Nielsen’s Melissa Davies, Research Director, Healthcare, Online division, will present testimony at an FDA hearing surrounding the pharmaceutical industry and regulations surrounding social media.

Melissa Davies
The FDA announced yesterday that it is launching a Transparency Task Force, charged with “making useful and understandable information about FDA activities and decision-making more readily available to the public in a timely manner and in a user-friendly format.” The task force will seek public input on how the FDA can be more transparent, including identifying “new technologies for informing the public.” To this end, there will be a public meeting on June 24, 2009, to solicit recommendations.

Melissa Davies
Last week brought an exciting new development for pharmaceutical companies interested in social media: blogger Mark Senak (EyeonFDA.com) posted an interview with an official from the FDA/Division for Drug Marketing, Advertising and Communications (DDMAC) about pharmas and Web 2.0. Until now, there has been so little mention of social media and the like from the FDA that many pharma companies have come to assume that Web 2.0 is strictly off-limits. The conversation that was started this week — though by no means the final word on whether and how …